Carboplatin or cisplatin
Phase 3Small molecule
Carboplatin or cisplatin is one of 116 small molecule programs targeting Chemotherapy. It is currently in Phase 3.
3
Indications
11
Total Trials
7
Active Trials
115
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
449 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Trodelvy
GileadPhase 3
Dato-Dxd
AstraZenecaPhase 3
Carboplatin or cisplatin
SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
TGRX-326
SShenzhen TargetRx Co., Ltd.
Phase 3
Remeron
OOrganon and Co
Preclinical
Valemetostat Tosylate
Daiichi SankyoPreclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer4 trials
Show 1 more trial
A Randomized, Open-Label, Multicenter Phase 3 Clinical Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Active, not recruiting·SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·Phase 3·NCT06711900·432 enrolled
Lung Cancer1 trial
Esophageal Squamous Cell Carcinoma1 trial
3 more indications
Small Cell Lung Cancer1 trial
Lung Cancer (Non-Small Cell)1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Carboplatin or cisplatin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details